Although regular aspirin use has been shown to lower the risk of colorectal cancer, its efficacy against lung cancer is weak or inconsistent. Moreover, aspirin use increases the risk of ulcers and stomach bleeding. In this study, we determined the efficacy of nitric oxide-donating aspirin (NO-Aspirin), a safer form of aspirin in which the parent drug is linked to a nitric oxide-releasing moiety through a spacer, to suppress lung tumorigenesis. Under in vitro conditions, NO-Aspirin significantly reduced the proliferation and survival of tumorigenic bronchial cell line (1170) and non-small cell lung cancer (NSCLC) cell lines (A549, H1650, H1975 and HCC827) and colony formation by NSCLC cells at sub-or low micromolar concentrations (≤1 µM for 1170 cells and ≤6 µM for NSCLC cells) in a COX-2 independent manner. These effects were paralleled by suppression of phospho-epidermal growth factor receptor (EGFR), -STAT3, -Akt and -ERK and enhanced caspase 3 and PARP cleavage. Among NSCLC cells, EGFR mutant cells (H1650, H1975 and HCC827) were more sensitive than cells expressing wild-type EGFR (A549) and H1650 cells were the most sensitive. Moreover, NO-Aspirin sensitized H1650 and H1975 cells to the antiproliferative effects of erlotinib, a tyrosine kinase inhibitor. In in vivo studies using 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) + lipopolysaccharide (LPS)-induced model of lung tumorigenesis, NO-Aspirin significantly reduced the number and size of lung tumors, expression of phospho-EGFR and -Akt as well as the pro-inflammatory molecules TNF-α and interferon-gamma. Overall, these results indicate the potential of NO-Aspirin for the chemoprevention of lung cancer in high risk populations.
Introduction
Lung cancer is one of the leading causes of death in the USA (1) . The American Cancer Society estimated that 222 500 new cases of lung cancer would be diagnosed in the United States by the end of 2017, and there would be 155 870 lung cancer-related deaths, accounting for ~27% of all cancer deaths. Although recent advances in cancer biology have led to the identification of new targets and the development of novel-targeted therapies, the survival of lung cancer patients still remains poor.
Epidermal growth factor receptor (EGFR), a tyrosine kinase (TK) member of the ErbB family, is one of the most frequently altered genes (protein overexpression, gene amplification, and mutations) in non-small cell lung cancer (NSCLC), which comprises of about 75% of lung cancer. EGFR mutation and/or amplification have been observed in histologically normal bronchi of patients with EGFR-mutant lung cancer (2) , histologically normal, and hyperplastic bronchial epithelium from smokers (3) , and atypical adenomatous hyperplasia of the lung (4), indicating that these alterations are early events in the pathogenesis of NSCLC. Thus, targeting altered EGFR with safe and effective drugs during the early phase of lung tumorigenesis could inhibit the development of NSCLC. However, EGFR tyrosine kinase inhibitors such as erlotinib and gefitinib are not appropriate candidates due to their severe adverse effects (5, 6) .
Nonsteroidal anti-inflammatory drugs have long been considered promising chemopreventive agents due to their antioxidant and anti-inflammatory properties (7) . Acetylsalicylic acid, commonly known as aspirin, is the archetype of the nonsteroidal anti-inflammatory drug family. Considerable evidence from epidemiological studies and randomized trials has demonstrated the potential of aspirin to prevent colorectal cancer (8, 9) although the data for other cancer sites, including the lung, are inconsistent (8, (10) (11) (12) (13) (14) . The reduced efficacy of aspirin against non-gastrointestinal cancers and the toxicities associated with its long-term use such as gastrointestinal bleeding and hemorrhagic stroke (15) led to the development of more potent and safe aspirin derivatives. One of these compounds is nitric oxide-donating aspirin (NO-Aspirin) in which a nitric oxide-donating group is attached to aspirin through a linker molecule. The rationale for the development of NO-Aspirin is the important role of NO in mucosal defense (16) . Additionally, NO-Aspirin was more potent than traditional aspirin in inhibiting the growth of colon cancer cells (2500-5000-fold more effective (17) ) and in reducing tumorigenesis in rodent models of cancer (18) (19) (20) . The exact mechanism through which NO-Aspirin inhibits cancer is not clear but different mechanisms have been reported, including inhibition of signaling cascades involved in cell proliferation and survival (21) (22) (23) , induction of phase 2 carcinogen detoxifying enzymes and suppression of DNA damage and adduct formation (24, 25) , induction (22) or inhibition (23) of Cyclooxygenase-2, and induction of oxidative stress (18) .
In this study, we observed that sub-or low micromolar concentrations of NO-Aspirin inhibited the proliferation of tumorigenic bronchial cell line (1170) and NSCLC cells and colony formation by NSCLC cells. NSCLC cell lines harboring EGFR mutation (H1650, H1975 and HCC827) showed differential sensitivity towards NO-Aspirin and the antiproliferative and apoptotic effects of erlotinib, an EGFR tyrosine kinase inhibitor, were significantly enhanced by NO-Aspirin. In subsequent studies using a mouse model of lung tumorigenesis, NO-Aspirin inhibited inflammation-driven lung tumorigenesis in A/J mice as reflected by significant reductions in the multiplicity of lung tumors, in particular bigger tumors, and tumor tissue levels of phospho-EGFR and phospho-Akt and inflammatory cytokines. Overall, our results showed the potential of NO-Aspirin to suppress lung tumorigenesis driven by EGFR overexpression or mutation and to enhance the efficacies of EGFR-targeted therapies.
Materials and methods

Chemicals and reagents
NO-Aspirin was provided by the NCI`s DCP repository and its chemical structure is shown in Figure 1A . Antiphospho-EGFR (Tyr 1068), antitotal EGFR, antiphospho-Akt (Ser 478), antitotal Akt, antiphospho-p44/42 MAPK (Thr202/Tyr204), antitotal p44/42 MAPK, antiphospho-STAT3 (Tyr 705), antitotal STAT3, anticaspase 3, anti-COX2, anti-β-actin and goat antirabbit IgG secondary antibody were from Cell Signaling Technology (Beverly, MA). Antipoly (ADP-ribose) polymerase (PARP) was obtained from Santa Cruz Biotechnology. Erlotinib was purchased from LC laboratories (Woburn, MA). NNK (99% of purity) was synthesized as described elsewhere (26) . Mouse diets (AIN-93G and AIN-93M) were purchased from Harlan Teklad (Madison, WI). These diets are standard diets for lung tumorigenesis studies in A/J mice. The AIN-93G diet, high in protein and fat, was used to support the rapid growth of the mice until 8 weeks of age. AIN-93G diet was then replaced by AIN-93M diet, a low-protein and low-fat diet, which is recommended for adult maintenance.
Cells and cell culture
Tumorigenic bronchial cell line (1170) was kindly provided by Dr. KleinSzanto (Fox Chase Cancer Center, Philadelphia). This cell line was developed from BEAS-2B cells explanted along with beeswax pellets containing cigarette smoke condensate into rat tracheas that had been denuded of bronchial epithelium and further transplanted into the dorsal subcutaneous tissues of nude mice (27) 
Cell viability assay
The effect of NO-Aspirin on cell viability was determined by methylthiazoletetrazolium (MTT; Biotium, Hayward, CA) assay as follows. NSCLC and 1170 cells were plated on a 24-well plate at a density of 30 000 cells/ well, grown for 24 h and treated with NO-Aspirin (0-1 μM for 1170 cells and 0-6 μM for NSCLC cells) for 24 h followed by MTT treatment (40 μl per well) for 4 h. Culture media were aspirated, 300 μl of dimethyl sulfoxide (DMSO) added to each well and absorbance read at 570 nm with a plate reader. Each treatment with DMSO or NO-Aspirin was carried out in triplicate and the assays were repeated three times on different days. The effect of NO-Aspirin on the cell viability was assessed as relative percentage of cell viability compared to DMSO-treated cells.
Annexin V/propidium iodide apoptosis assay
To determine the apoptotic effects of NO-Aspirin, 1170 and NSCLC cells were treated with the drug (0-1.0 μM for 1170 cells and 0-6.0 μM for NSCLC cells) for 24 h. Subsequently, 1 × 10 6 cells were washed twice with cold phosphate-buffered saline and stained with 5 μl Annexin V-fluorescein isothiocyanate (BD Pharmingen, San Diego, CA) and 5 μl propidium iodide (5 μg/ml, BD Pharmingen, San Diego, CA) in binding buffer for 20 min at room temperature in the dark. The apoptotic cells were determined using a Becton Dickinson LSRII flow cytometer. The assay was carried out three times.
Colony formation assay
Cells treated with DMSO or NO-Aspirin (0-6.0 μM) for 6 h were seeded in six well culture plates and incubated for 2 weeks in RPMI 1640 medium supplemented with 10% FBS in the absence of NO-Aspirin. The colonies were stained for 10 min at room temperature with 0.5% crystal violet prepared in 30% ethanol. After washing out the dye with tap water, colonies were counted. Assays were performed in three times on different days.
Tumor bioassay
The study design for the tumor bioassay is depicted in Figure 4A . Briefly, 6-week-old female A/J mice were obtained from the Jackson Laboratory (Bar Harbor, ME) and housed in the specific-pathogen-free animal quarters of Center. After 1 week of acclimatization, mice were randomized into three treatment groups (10 mice for group 1and 20 mice each for groups 2 and 3). Mice in group 1 received physiological saline solution, the vehicle control. Mice in groups 2 and 3 were treated with two doses of NNK (100 mg/kg, i.p.) at an interval of a week. Beginning 1 week after the second NNK dose, LPS (5 µg/mouse in 50 μl of phosphate-buffered saline) was intranasally administered to both groups of mice once a week for 14 weeks. NO-Aspirin was added to the diet of mice in group 3 (3000 ppm in diet) beginning 1 week after the second dose of NNK until the end of the study, while mice in groups 1 and 2 were maintained on non-supplemented diet. The dose level of NO-Aspirin was determined based on previous studies (23) . Food consumption was measured two times a week, and body weights were determined weekly throughout the study. At week 16, the mice were euthanized with an overdose of carbon dioxide. The lungs were harvested, and the number and size of tumors on the surface of the lung were determined under a dissecting microscope. The collected lung lobes were either stored at −80°C for western immunoblotting studies or kept in RNAlater solution for RNA isolation. 
Western immunoblotting assay with cell lysates and mouse lung tissue homogenates
Cell lysates were prepared from 1170 and NSCLC cells by incubating the cells in 1× RIPA buffer containing a cocktail of protease and phosphatase inhibitors (Pierce, Rockford, IL) for 10 min on ice. For the preparation of lung tissue homogenates, whole lungs were homogenized in the same buffer. Subsequently, cell and tissue lysates were centrifuged at 14 000 g for 10 min at 4°C, supernatants collected, aliquoted and stored at −80°C. For Western immunoblotting assay, 20 μg protein from the cell lysates or 50 μg protein from lung tumor tissue lysates were resolved over 4-12% Novex Tris-glycine gels (Invitrogen, Carlsbad, CA) and transferred to a PVDF membrane (Bio-Rad). The blot was blocked in blocking buffer [5% non-fat dry milk in Tris-buffered saline with Tween 20 (TBST) buffer] for 1 h at room temperature, incubated with appropriate primary antibodies at 4°C overnight. Subsequently, the membrane was washed with TBST and incubated with the appropriate horseradish peroxidase-conjugated secondary antibody for 1 h at room temperature. The protein-antibody complexes were detected by enhanced chemiluminescence (ECL kit) in accordance with the manufacturer's directions (Pierce, Rockford, IL). Biotinylated protein ladder (cell signaling technology) was loaded into the first left lane of each gel and used as the molecular weight marker to detect target band. The protein-antibody complexes were detected by enhanced chemiluminescence (ECL kit) in accordance with the manufacture's manual (Pierce, Rockford, IL). For each protein, at least three western blot assays were carried out. To quantify protein levels, densitometric measurements of Western blot bands were performed using digitalized scientific software program UN-SCAN-IT software (Silk Scientific, Orem, Utah). Assays were carried out at least three times.
Quantitative reverse transcription-PCR analysis
Total RNA was extracted using the miRNeasy Mini Kit (Qiagen, Valencia, CA) according to the manufacturer's instruction. The purity and integrity of total RNA were confirmed by Nanodrop. The first-strand complementary DNA was synthesized and quantitative reverse transcription-PCR performed following standard procedures using gene-specific forward and reverse primers (See Supplementary Table 1, available at Carcinogenesis Online). All samples were normalized to an internal control gene, β-actin and the comparative Ct method was used to assess the relative gene expression. Samples were tested in triplicates and repeated three times.
Statistical analysis
Results from lung tumor bioassay are reported as mean ± SD of 10 mice (control group) or 20 mice (treated groups), whereas Western immunoblotting and MTT assays are reported as mean ± SD of triplicate determinations. Between group comparisons were performed using one-way ANOVA and two-tailed t-test using GraphPad Prism 5 software (GraphPad, La Jolla, CA). P-values < 0.05 were considered significant.
Results
NO-Aspirin reduced cell proliferation and induced apoptosis in tumorigenic bronchial cell line
To determine the antiproliferative effects of NO-Aspirin on tumorigenic 1170 bronchial cells, the cells were incubated with different concentrations of the drug for 24 h and cell proliferation was determined by MTT assay. As depicted in Figure 1B 
NO-Aspirin modulated levels of cell proliferationand apoptosis-related proteins in 1170 cells
Several previous studies have reported that the anticancer activities of aspirin are mainly dependent on targeting of COX-2 and related proteins (28, 29) , although COX-2-independent effects have also been reported (30, 31) . Therefore, we first assessed expression of COX-2 in 1170 cells and if NO-Aspirin modulates the expression of this protein. Figure 1D shows that A549 cells, the control cells, but not 1170 cells expressed COX-2. To identify other potential targets of NO-Aspirin in 1170 cells, we analyzed the expression of a panel of cell proliferation-and survival-related proteins. No-Aspirin suppressed both constitutive as well as epidermal growth factor (EGF)-stimulated phospho-EGFR, phospho-Akt, phospho ERK and phospho-STAT3 in a dosedependent manner as early as 3 h and even stronger effects were observed at 24 h ( Figure 1E and F) . In line with the results of the apoptosis assay, treatment of 1170 cells with NO-Aspirin for 24 h induced cleavage of caspase 3 and PARP, markers of apoptosis. In further studies carried out to assess if induction of reactive oxygen species or reactive nitrogen species were involved in the antiproliferative and apoptotic effects of NO-Aspirin, the antioxidant drug N-acetyl-L-cysteine (NAC) and the NO scavengers (hemoglobin and PTIO) and NO donor (DETA NONOate) failed to modulate the effects of NO-Aspirin (Data not shown).
Differential antiproliferative and apoptotic effects of NO-Aspirin in EGFR mutant NSCLC cells
Since the assays with 1170 cells indicated that NO-Aspirin reduced EGFR phosphorylation, we further pursued these studies and compared the effects of the drug in EGFR wild-type (A549) and EGFR mutant (H1650, H1975 and HCC827) NSCLC cell lines. Interestingly, NO-Aspirin induced significantly higher antiproliferative effects in the three EGFR mutant cell lines than in EGFR wild-type A549 cells, in particular at lower concentrations of the drug. For instance, whereas 2.0 and 4.0 µM of NO-Aspirin reduced the proliferation of A549 cells by 17 and 36%, respectively, the growths of H1650, H1975 and HCC827 cells were reduced by 66, 37 and 36% at 2.0 µM and by 76, 63 and 67% at 4.0 µM, respectively (Figure 2A) . Similarly, exposure of A549 cells to 2.0 and 4.0 µM of NO-Aspirin led to apoptosis in 4 and 12% of the cells, respectively; the values for H1650, H1975 and HCC827 cells were 61, 19 and 26% at 2.0 µM and 65, 40 and 44% at 4.0 µM, respectively. Also, in colony formation assay, which indicates anchorage-independent growth, colonies formed by NSCLC cells were reduced by NO-Aspirin in a dose-dependent manner and the lowest number of colonies were seen in H1650 and HCC827 followed by H1975 cells, whereas A549 cells formed colonies even at the highest concentration ( Figure 2B and C) .
In line with its differential antiproliferative and apoptotic effects in EGFR mutant NSCLC cells, NO-Aspirin suppressed levels of phosphorylated-and total-EGFR, Akt, ERK and STAT3 and increased the cleavage of caspase 3 in H1650, H1975 and HCC827 cells in a dose-dependent manner. On the other hand, in A549 cells, no changes were seen at 2 and 4 µM and moderate reduction in phospho-EGFR, EGFR and phospho-Akt were observed at 6 µM of NO-Aspirin ( Figure 2D ). In cell lines that express COX-2 (A549 and HCC827 cells), NO-Aspirin reduced the level of the protein only at the highest concentration. Since NO-Aspirin reduced the expression of β-actinin H1650 cells, Coomasie blue staining was used to show equal protein loading ( Figure 2D ).
To determine if NO-Aspirin enhances the antiproliferative and apoptotic effects of the tyrosine kinase inhibitor drug erlotinib, EGFR-mutant H1650 and H1975 cells were treated with erlotinib (5 µM) and NO-Aspirin (0.75 µM) for 72 h, individually or in combination. As shown in Figure 3A , NO-Aspirin, erlotinib and NO-Aspirin + erlotinib reduced the proliferation of H1650 cells by 60, 21 and 83%, respectively. In H1975 cells, which were relatively more resistant to NO-Aspirin but more sensitive to erlotinib, compared to 1650 cells, the combinatory effects were weaker (NO-Aspirin, erlotinib and NO-Aspirin + erlotinib reduced cell proliferation by 10, 44 and 54%, respectively). In agreement with the results of the cell proliferation assay, H1650 cells treated with NO-Aspirin + erlotinib exhibited lower levels of phospho-Akt, Akt, phospho-STAT3 and STAT3, but stronger reduction of caspase 3 and PARP, compared to cells treated with the individual drugs. In H1975 cells, NO-Aspirin alone failed to modulate the expression of any of the above proteins. However, cells treated with NO-Aspirin + erlotinib exhibited markedly lower levels of phospho-EGFR, phospho-ERK, ERK, phospho-STAT3 and STAT3 compared to cells treated with NO-Aspirin or erlotinib alone ( Figure 3B ).
NO-Aspirin suppressed the multiplicity and size of NNK+ LPS-induced lung tumors
To further corroborate the chemopreventive activities of NO-Aspirin, mice pre-treated with the tobacco smoke carcinogen NNK and then exposed to the inflammatory agent LPS were maintained on diet supplemented with NO-Aspirin (3000 ppm) and the number and size of tumors on the surface of the lung as well as levels of cell proliferation-and survival-related proteins and proinflammatory cytokines were determined. NO-Aspirin had no apparent adverse effects on the mice as determined by food consumption and body weight measurements (data not shown).
The positive control group treated with NNK + LPS had 23.2 ± 8.0 lung tumors/mouse, whereas the group treated with NNK + LPS and given NO-Aspirin in the diet exhibited 16.0 ± 4.1 lung tumors/mouse, corresponding to a significant reduction of tumor multiplicity by 31% ( Figure 4B ). Moreover, stratification of the lung tumors into different size classes indicated that NO-Aspirin significantly reduced the number of bigger lung tumors (1-2 and >2 mm) by about 67%, whereas smaller tumors (less <1 mm) were slightly increased ( Figure 4C ), indicating that NO-Aspirin suppressed the growth of lung tumors. In an attempt to throw light into the potential mechanisms responsible for the antitumor effects of NO-Aspirin, we compared expressions of cell proliferation-and -survival-related proteins in lung tissues from untreated and NNK + LPS-or NNK + LPS + NO-Aspirin-treated mice. As shown in Figure 5A and B, lung tissues from mice treated with NNK+LPS had a significantly higher level of total and phospho-EGFR, total and phospho-Akt and phospho-ERK compared to the level in untreated control mice. Administration of NO-Aspirin significantly reduced levels of phospho-EGFR and -Akt, whereas expressions of total EGFR, Akt and ERK were not modulated. 
Dietary administration of NO-Aspirin to NNK-and LPS-treated mice reduced the expression of proinflammatory genes in lung tumor tissues
Chronic inflammation is mediated by a variety of molecules which play a role in the initiation and/or promotion of tumorigenesis via induction of DNA damage and modulation of cell proliferation and survival, cell migration and invasion and tumor metastasis (32) . To determine whether NNK+LPS or NO-Aspirin modulated the expression of these mediators, we determined the expression of some prototype pro-inflammatory molecules in lung tissues. As shown in Figure 6 , levels of TNF-α and IFN-γ were significantly increased in the groups treated with NNK + LPS compared to the level in the control group and NO-Aspirin significantly reduced the expression of these cytokines. Although not significant, a similar trend was observed for IL-17a. The expression of COX-2 was not altered by NO-Aspirin (data not shown).
Discussion
In this study, we showed that sub-or low micromolar concentrations of NO-Aspirin significantly reduced cell proliferation, survival and colony formation in in vitro models of lung tumorigenesis. Mechanistically, NO-Aspirin inhibited phosphorylation of EGFR and its downstream effectors including Akt, STAT3 and ERK. Among NSCLC cells, EGFR mutant cells (H1650, H1975 and HCC827) were more sensitive than EGFR wild-type cells (A549) to the effects of NO-Aspirin. Moreover, NO-Aspirin enhanced the antiproliferative and apoptotic activities of the TKI erlotinib in EGFR mutant NSCLC cells. The results in cell line models were further corroborated in a mouse model of lung tumorigenesis in which NO-Aspirin significantly reduced the number of NNK+LPS-induced lung tumors, in particular larger tumors, and these effects were paralleled by reduced activation of EGFR and Akt as well as the expression of pro-inflammatory molecules in tumor tissues.
Aspirin, the parent drug for NO-Aspirin, has been shown to inhibit cigarette smoke-induced lung adenoma in female mice via inhibition of DNA adducts, oxidative DNA damage and/ or COX-2-mediated and aromatase-catalyzed estrogen biosynthesis (33) . Similarly, aspirin inhibited NNK-induced lung tumorigenesis by blocking COX-2-mediated bioactivation of NNK or NNK-induced immunosuppression (34) (35) (36) . Although it is not appropriate to directly compare these reports with our present findings (different models and temporal sequence of drug administration), in previous reports, NO-Aspirin was found to be more effective than aspirin in suppressing the growth of colonic pre-neoplastic lesions in rats and these effects were independent of modulation of COX-1 and COX-2 (37). Likewise, NO-Aspirin reduced N-nitrosobis (2-oxopropyl) amine-induced pancreatic tumors in golden Syrian hamster by 89%, whereas equimolar concentrations of aspirin reduced tumor incidence by only about 30% (38) . The higher anticancer effects of NO-Aspirin versus aspirin were more evident in in vitro models. Comparison of the antiproliferative activities of NO-Aspirin and aspirin in seven human cancer cell lines showed that NO-Aspirin was 44-6900-fold more potent than that of aspirin and these effects were independent of COX-1 or COX-2 expression (39). In the present study, the IC 50 of NO-Aspirin in 1170 cells (<1 µM) was much lower than that of aspirin (10 mM, data not shown). Among NSCLC cell lines, cells harboring EGFR mutation (H1650, H1975 and HCC827) were more sensitive to the antiproliferative and apoptotic activities of NO-Aspirin than the EGFR wild-type A549 cell line and H1650 cells were the most sensitive of the three cell lines followed by HCC827 cells. The reasons for the differential sensitivity of EGFR mutant cells towards NO-Aspirin are unclear. H1650 and HCC827 cell lines with an exon 19 deletion were also found to be more sensitive to the antiproliferative and apoptotic effects of EGFR siRNA than H1975 cells suggesting that exon 19 mutation is highly oncogenic and addictive (40) .
Chronic inflammation is implicated as a cause of lung cancer since components of inflammatory pathways play a critical role in many aspects of lung tumorigenesis, including DNA damage, proliferation and survival of tumor cells, angiogenesis, and tumor metastasis (32) . One of the key drivers of chronic inflammation is COX-2 and the link between chronic inflammation, COX-2, and lung cancer led to the wide use of NSAIDs including aspirin to target COX-2. However, in the present study, the antiproliferative, apoptotic and antitumor effects of NO-Aspirin were independent of COX-2 expression since COX-2-negative cells (1170, H1650 and H1975) showed similar or higher sensitivity to NO-Aspirin compared to COX-2 positive cells (A549 and HCC827). Also, NO-Aspirin failed to modulate COX-2 levels in mouse lung tumor tissues.
These findings suggest the existence of other potential mechanisms through which NO-Aspirin induced its anticancer effects. Indeed, we found that NO-Aspirin suppressed phosphorylation of EGFR and its downstream effectors Akt, ERK and STAT3 in tumorigenic bronchial 1170 cells as well as in NSCLC cell lines (A549, H1650, H1975 and HCC827). These results are consistent with a previous report in which NO-Aspirin induced significant induction of cell cycle arrest and apoptosis in cisplatin-resistant human ovarian cancer cells via downregulation of EGFR/PI3K/STAT3 (41) . However, the mechanism through which NO-Aspirin inhibits the EGFR signaling axis is unknown. The NO moiety of the drug could play a role in the suppression of the EGFR pathway as exogenous and endogenous NO prevented EGF-induced transphosphorylation of the EGFR and the subsequent phosphorylation of Akt (42) . However, co-treatment of NSCLC cells with NO-Aspirin and the NO scavengers, hemoglobin and PTIO failed to modulate phosphorylation of EGFR/STAT3/Akt or the antiproliferative and apoptotic activities of NO-Aspirin.
In conclusion, our findings showed that NO-Aspirin inhibited lung tumorigenesis in vitro and in vivo and these effects were associated with reduced activation of EGFR and its downstream effectors. The superior cancer preventive activities and improved gastrointestinal safety profile of NO-Aspirin, compared to the parent drug aspirin, indicates that this drug should be prioritized for clinical lung cancer chemoprevention trials, in particular in subjects harboring alterations in EGFR. Moreover, NO-Aspirin could be used to overcome acquired resistance to EGFR tyrosine kinase inhibitors.
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